Harvard Apparatus Regenerative Technology, Inc. — fact timeline

Harvard Apparatus Regenerative Technology, Inc. entered into Purchase Agreement with certain investors valued at aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 m (effective 2025-12-30).

“Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”), each effective as of December 30, 2025, with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate purchase price of approximately $0.7 million and a purchase price per share of $1.70 (the “Private Placement”).”

Mao Zhang was appointed as Class I Director at Harvard Apparatus Regenerative Technology, Inc..

“On August 26, 2024, Mao Zhang, the Founder and Chief Executive Officer of Stellars Capital, joined the Board of Directors (the “Board”) of the Company as a Class I director.”

Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors valued at $1.5 million (effective 2024-04-15).

“On April 15, 2024, Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 367,767 shares of common stock for the aggregate purchase price of $1.5 million and a purchase price per unit of $4.03 (the “Private Placement”).”